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1. Introduction
The objectives of this chapter are to review clinical and pathophysiologic aspects of fibrosis
in inflammatory bowel disease, particularly in Crohn’s disease. Potential therapeutic strat‐
egies and the current status of preclinical animal models to evaluate these therapeutic strat‐
egies will also be discussed.
2. Clinical considerations
Crohn’s disease (CD) and ulcerative colitis (UC) are chronic, relapsing inflammatory gastro‐
intestinal diseases which often onset in young adulthood. Unlike in UC, where inflamma‐
tion is limited to the mucosa, CD patients frequently develop transmural disease which can
extend to involve the muscularis and serosa. While inflammatory disease accounts for much
of the symptomatology associated with CD, significant morbidity results from fibrotic le‐
sions and their resulting complications.
CD can be broadly categorized as having three major clinical subtypes: stricturing, penetrat‐
ing or inflammatory (nonstricturing nonpenetrating) disease [1]. This categorization is re‐
flected by the inclusion of disease behavior ( stricturing, penetrating or inflammatory) as
one of three variables elected for inclusion in the Vienna classification in 1998 [2]. Review of
natural history data from shows that the majority of patients undergo progression from in‐
flammatory disease to development of complications including stricture [3]. Even though
most patients present with inflammatory disease only and later progress to a more compli‐
cated disease phenotype, a subset of patients will present with stricturing or penetrating dis‐
ease. In population-based studies, 19-36% of patients newly diagnosed with CD present
with disease complications such as strictures, fistulas or abscesses [4-6].
© 2012 Diehl; licensee InTech. This is an open access article distributed under the terms of the Creative
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Intestinal stricture is a common and serious complication of long term CD. Critical intestinal
stricture formation will occur in at least one-third of CD patients within 10 years of onset
[7-9]. By contrast, fibrosis associated with UC is generally limited to the mucosa and stric‐
ture formation is rare although rectal strictures, when they occur, can be problematic to
manage [10]. Advances in CD treatment have yet to make significant impact on the inci‐
dence of strictures and the associated morbidity [11].
While surgical resection is a highly effective short term treatment, remission after surgical
resection in CD is only temporary. The disease course in CD patients postsurgery is relative‐
ly consistent and has allowed development of a postoperative recurrence model [12, 13]. In
this model, a focal inflammatory infiltrate forms in the ileum above the anastomosis fol‐
lowed by aphthous ulcers which are endoscopically visible in two-thirds of patients within 3
months after surgery. These patients go on to develop extensive superficial and deep ulcers
that precede the development of a new stricture. Postoperative reoccurrence is very com‐
mon with fewer than 5% of patients having normal endoscopy results 10 years after surgery.
Symptoms occur on average 2-3 years after lesions are observed.
In patients with a fibrostenotic disease behavior, symptomatic strictures tend to return de‐
spite medical therapy and this leads to repeated bowel resections and eventually to short
bowel syndrome [14-16]. Endoscopic balloon dilation can provide a treatment option for pa‐
tients with fibrostenotic strictures 7 cm or less in length although there is some risk of perfo‐
ration [17, 18]. Strictureplasty can be a useful bowel-preserving surgical option for stenosing
small bowel CD in patients with multiple obstructions and in those vulnerable to short bow‐
el syndrome [19]. The incidence of postoperative recurrence is very similar between strictur‐
eplasty and resection [11].
Strictures can arise due to either inflammatory or fibrotic processes. There is evidence that
direct steroid injection can provide symptom relief in some CD patients with anastomotic
strictures, presumably in patients with active inflammation and relatively little fibromuscu‐
lar proliferation at the anastomotic site [18]. Given the risk of multiple bowel resection sur‐
geries and the possibility of short bowel syndrome, the ability to differentiate between
inflammatory or fibrotic strictures could be used to drive treatment decisions. Endoscopy-
based techniques such as colonoscopy, small intestinal endoscopy, and capsule endoscopy
have high clinical utility but only visualize the mucosal surface. Cross-sectional imaging
techniques can be used to visualize deep layers of the intestinal wall and assess for stric‐
tures. Computed tomography enterography (CTE) has become the most widely used cross-
sectional imaging technology for CD although concern about cumulative radiation
exposure, particularly in young patients, has led to interest in alternative imaging modali‐
ties [20, 21].
Imaging methods such as magnetic resonance (MR) enterography or ultrasonography are ef‐
fective in determining the anatomic location and length of affected intestinal segments and
these techniques, as well as CTE, have shown a good correlation with endoscopy [22-24].
However, distinguishing stricture composition remains a challenge. In 2006, the European
Crohn’s and Colitis Organization (ECCO) stated in their consensus report on treatment of
CD that current techniques are insufficiently accurate to differentiate between inflammatory
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and fibrostenotic strictures [25]. A recent study confirms that, while the combination of MR-
enterography and ultrasound as well as the combination of 18FDG-PET/CT and ultrasound
are highly efficient in detecting CD strictures, no current imaging techniques shows suffi‐
cient sensitivity or specificity to reliably differentiate inflamed from fibrotic strictures [26].
The clinical need for this for such differentiation remains high and may require both techno‐
logic advancement and establishment of criteria for grading or distinguishing strictures
which contain both fibrotic and inflammatory components [27]. [25]. In clinical practice, a
variety of diagnostic tools including imaging techniques and inflammatory biomarkers are
often applied in an effort to obtain sufficient evidence to inform treatment decisions [28].
Therapeutic strategies have evolved over the past decade and having the ability to predict
disease outcomes could guide the clinician’s choice of therapy. The goals of CD treatment
should include 1.) steroid-free sustained clinical remission; 2.) mucosal healing; 3.) potential
induction and maintenance of radiological healing; 4.) prevention of surgery; 5.) mainte‐
nance of normal gastrointestinal function; and 6.) prevention of disability [6]. There are a
number of therapeutic options available for the treatment of inflammation in CD patients,
however none of these have been demonstrated to be effective in preventing preventing or
treating fibrostenosis thereby failing to achieve at least 2 of the 6 major treatment goals in
patients with fibrostenotic disease. There have been some reports of regression of strictures
and of overall benefit following infliximab treatment in a subset of patients with small bow‐
el stricturing disease [18, 29, 30]. This data is largely anecdotal and remains controversial as
large controlled trials have not yet been performed.
In CD, disease location (ileal vs. colonic) remains relatively stable but clinical behavior can
alter significantly over time [8, 31, 32]. During the first few years of disease, inflammatory
forms predominate, whereas, after 40 years, most patients have experienced complications
and are classified as having penetrating or stricturing disease[33]. However, the rate at
which disease behavior evolves can vary widely between CD patients and those differences
would determine therapeutic strategies if rapidly progressing patients could be identified.
For example, initiation of more aggressive treatment early in the course of disease has the
potential to result in better outcomes, however, these therapies can also lead to greater risk
of toxicity and adverse effects [34, 35]. Decisions on whether to use a conservative or an ag‐
gressive treatment strategy in newly diagnosed patients could be informed by the ability to
identify patients at higher risk for developing disabling or complicated disease.
3. Fibrosis risk factors
A number of retrospective studies have identified specific disease characteristics that may
be of use in predicting risk for individual CD patients. These include an initial CD diagnosis
under age 40, need for steroid therapy at diagnosis, and perianal fistulizing disease [31, 36].
Localization of inflammation to the small bowel has also been identified as predictive of
progression to more complicated disease and higher rate of surgery [37]. However, all of
these clinical features tend to correlate with the presence of small intestinal disease and do
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not necessarily identify which patients with small bowel disease are at greatest risk of devel‐
oping fibrostenosing disease.
Genetic polymorphisms play an important role in susceptibility to CD so the use of genetic
markers to provide risk stratification and drive clinical decisions is very attractive. The ob‐
servation that some CD patients are susceptible to stricture development early and often in
their clinical course while others never develop a stenosing phenotype argues for the exis‐
tence of a genetic background which predisposes to stricturing behavior in CD.
One of the genes linked with susceptibility to CD is the CARD15/NOD2 gene which encodes
a protein involved in bacterial recognition and activation of nuclear factor kB. Carriers of
two mutant alleles have 17 to 42 times the risk while carriers of one mutation have 1.5 to 3
times the risk of developing CD [38, 39]. There is a significant body of evidence suggesting
that the main NOD2/CARD15 variants (Arg702Trp, Gly908Arg, and Leu1007insC) are asso‐
ciated with risk for developing stenotic disease and increased need for surgery [40-44].
However, this finding is not reproducible in every CD cohort evaluated [45, 46]. One large
meta-analysis of the NOD2/CARD15 literature indicated that carrying at least one NOD2/
CARD15 variant increased the risk of both small intestinal disease and of the stenosing phe‐
notype [47]. The discrepancy between studies may be due to differences in definitions of dis‐
ease behavior between studies and, perhaps, to the particular genetic epidemiological
analyses used. At present, understanding whether the relationship between the NOD2/
CARD15 variants and a stenosing phenotype is a true association or whether it instead re‐
flects aspects of disease duration and ileal localization remains a matter of controversy.
Other gene polymorphisms have been described as associated with a fibrostenotic pheno‐
type although the existing data is much less extensive than that available for NOD2/
CARD15. The ATG16L1 gene encodes for a protein involved in autophagy and mutations in
this gene have been associated with stricturing disease as well as perianal involvement in
CD [48]. CX3CR1, the receptor of CX3CL1 (fractalkine), is involved in regulation of inflam‐
matory response and the V249I polymorphism has been reported to be associated with in‐
testinal strictures [49]. A recent study linked the receptor for advanced glycation
endproducts (RAGE) -374T/A polymorphism to protection from stricturing phenotype in
CD. The polymorphism increases RAGE gene transcription which may provide protection
by increasing levels of soluble RAGE leading to neutralization of proinflammatory media‐
tors [50]. Some fibrostenosis-related polymorphisms have been observed in combination
with NOD2/CARD15. CXCL16 is a chemokine involved in bacterial defense mechanisms.
CD patients with at least one CXCL16 p.Ala181Val allele and one CARD15/NOD2 variant
had a higher incidence of stricturing and penetrating phenotype as well as stenosis as pa‐
tients with the NOD2 variant alone [51].
Despite their potential, genetic markers may never fully be able to predict the clinical course
of CD. The low frequency, incomplete penetrance, and interplay with other genetic poly‐
morphisms greatly complicate interpretation of genetic markers. In addition, environmental
factors can modulate disease history and impact phenotypic features. It is probable that ge‐
netic markers will need to be integrated with other clinical and serologic information in or‐
der to be useful predictors of disease course and to inform treatment decisions.
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4. Serologic biomarkers
Serologic markers may identify CD patients at higher risk of developing disease-related
complications. Some of the best characterized serologic markers associated with CD are di‐
rected against microbial peptides. Most of the available data is from cross sectional studies
in which the patient samples analyzed have been collected at various times in the disease
course allowing for comparison of serum from before, concomitant with, and after diagnosis
or treatment of bowel stricture.
Disease progression from non-complicated CD to stricturing and/or penetrating phenotypes
has been significantly associated with the presence and magnitude of serologic response to
microbial antigens. This concept was initially triggered by the observation that high anti-
Saccharomyces cerevisiae antibody (ASCA) levels were found to be associated with fibroste‐
nosing and penetrating disease and with the need for surgery [52]. This observation was
repeated in another cross sectional study where ASCA positive patients were more likely to
undergo surgery within 3 years of diagnosis than ASCA negative patients [53]. Time to first
complication was shown to be shorter in ASCA positive pediatric CD patients than in ASCA
negative patients [54]. In addition, anti-I2 (an antibody directed against Pseudomonas fluores‐
cens), anti-OmpC (the outer membrane porin protein of Escherichia coli) and anti-CBir1 (an‐
ti-flagellin) levels have also been shown to associated with fibrostenotic disease [55-60]. A
multi-center study evaluated the association of ASCA, anti-I2, anti-OmpC, and anti-CBir1
reactivity with disease course in a large cohort of pediatric CD patients and found that the
frequency of fibrostenotic or penetrating disease increased in parallel with the number of
antigens recognized [61]. Combining anti-microbial antibody titers and evaluation of NOD2
variants or other gene polymorphisms may improve detection of patients at higher risk of
developing fibrostenotic disease [62].
The predictive value of other serologic markers for fibrostenotic disease has been evaluated
on a much more limited basis than the anti-microbial antibodies. C-reactive protein (CRP) is
widely used to monitor inflammatory disease activity and one prospective study found a
significant association between CRP levels and subsequent risk of intestinal resection in pa‐
tients with ileal disease [63]. Despite the prominent place of extracellular matrix proteins in
composition of fibrostenotic lesions, little association has been found with levels of these
molecules in the circulation [64]. However, one study did find that higher levels of plasma
fibronectin were associated with stricture formation in CD patients [65]. Growth factors
have also been evaluated in a limited fashion. Serum levels of YKL-40, a mammalian glyco‐
protein member of the chitinase family, has been reported as increased in CD patients with
stricturing disease compared to those without strictures [66]. Another study found serum
levels of basic fibroblast growth factor, a cytokine promoting fibroblast activation and prolif‐
eration, were higher in CD patients with intestinal strictures compared to patients with fis‐
tulizing or inflammatory phenotypes [67]. Prospective studies will be required to determine
which, if any, of these serologic tests may have potential as a clinically useful biomarker of
fibrostenotic disease.
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5. Histologic features
Stricture due to fibrostenotic change resulting in chronic obstruction is a major pathologic
event in chronic CD. Histologically, CD strictures are characterized by hyperplasia of the in‐
testinal muscle layers which is typically manifest as islands of smooth muscle cells in the
submucosa surrounded by dense collagen deposits. These regions of smooth muscle prolif‐
eration may become so extensive that they obliterate the submucosa [68]. Transmission elec‐
tron microscopy studies show alteration of muscle cells of the muscularis propria, especially
the inner muscle layer, including hypertrophy, synthesis and deposition of collagen, and fo‐
cal cellular necrosis [69].
Despite the general categorization of strictures as inflammatory, fibrostenotic or both, fibro‐
sis is often well correlated with inflammation and the majority of strictures contain some de‐
gree of both processes [70]. When histologic tissue inflammation and fibrosis were
compared in a relatively small cohort of patients undergoing surgical resection, the authors
found that all specimens which were significantly fibrotic were also significantly inflamed
[71]. This may accurately reflect the reality of stricturing disease in many patients, however,
this has not yet been confirmed in studies of larger patient cohorts and the results may be
skewed because histologic evaluation is only possible in patients undergoing surgical resec‐
tion. This excludes stricture patients who either respond to aggressive medical therapy or
who undergo bowel-sparing procedures which may inadvertently exclude many patients
who fall on either end of the inflammation/fibrosis spectrum.
Further  consideration  of  the  relationship  between  histologic  categorization  and  disease
behavior is needed and new histologic scoring systems may be required which consider
cellular  composition  or  other  features  in  order  to  more  effectively  categorize  strictures.
One retrospective study has been published where biopsies were evaluated to determine
if  certain  histologic  characteristics  correspond  to  eventual  development  of  complicated
CD [72]. The authors report that severe lymphoid infiltration of the lamina propria with
crypt atrophy and absence of intraepithelial lymphocytes correlates with non-stricturing/
non-penetrating  disease  while  these  features  were  absent  in  80%  of  CD  patients  with
stricturing  disease.  Once  again,  these  findings  were  based  on  a  small  cohort  size  and
need further evaluation but do accord with the larger concept of inflammatory vs. fibros‐
tenotic stricture processes.
Other studies comparing histologic features with biologic behavior are limited. At least two
studies have noted an association of mast cells in the submucosa and especially in the mus‐
cularis propria with stricture formation in CD patients [73, 74]. When compared to normal
bowel or non-strictured CD bowel, mast cell numbers were significantly higher in the thick‐
ened muscularis propria of CD strictures. No increase in mast cells was associated with ul‐
cerative colitis or other intestinal inflammatory conditions. Also, epitheliold granulomas
have been implicated as a risk factor for progression to complicated disease behavior. Epi‐
theliod granulomas are one of the most characteristic histologic features in biopsies or re‐
sected tissue from patients with CD although only about 15-25% of patients present with
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this lesion. Several studies have shown an association between the occurrence of epitheliod
granulomas, especially at presentation, and a more aggressive disease course [75].
6. Pathophysiology of fibrosis
Tissue injury or inflammation triggers a cascade of wound healing activities in the sur‐
rounding cell populations. Normal wound healing is a tightly regulated and coordinated
series of events triggered by secretion of mediators from activated immune and mesenchy‐
mal cells which induce cell proliferation, migration, and extracelluar matrix (ECM) produc‐
tion. Wound healing activity is followed by resolution of inflammation and tissue
remodeling. A balance must be achieved between processes involved in ECM production
and degradation and those involved in cellular hyperplasia (proliferation and cell death). In
the intestinal tract, tissue repair and regeneration are of great importance in mucosal ho‐
meostasis and intestinal barrier function. Rapid wound healing and restitution of an intact
mucosal barrier is crucial for controlling mucosal inflammation. However, excessive wound
healing response can result in fibrosis and stricture formation while insufficient tissue repair
can result in fistula formation.
The classic model of wound healing has 4 phases: hemostasis, inflammation, proliferation,
and remodeling [76, 77]. In the hemostasis phase, platelet degranulation and fibrin forma‐
tion provide both hemostasis and a provisional matrix for subsequent healing events to take
place. Cytokine and chemokine expression, initially by the innate immune system and later
including the adaptive immune system, drives the inflammatory phase. During the prolifer‐
ative phase, activated fibroblasts and myofibroblasts secrete collagen and other matrix mole‐
cules which provide a granulation tissue scaffold on which tissue structure repair can
commence. During the proliferative phase, cytokines and growth factors regulate reconstitu‐
tion of the mucosal epithelium allowing closing of the epithelial defect. Angiogenesis and
lymphangiogenesis also take place during this phase and there is expansion of the fibro‐
blast/myofibroblast population with concomitant ECM production. Finally, in the remodel‐
ing phase, myofibroblasts produce matrix-modifying molecules which assist in the restoring
anatomic structural integrity and completing the transition from wound to normal or near
normal intestine architecture.
When severe mucosal tissue damage occurs, myofibroblasts migrate to the edges of the tis‐
sue defect. The ability of myofibroblasts to migrate to the wound area and synthesize ECM
proteins is critical in proliferative phase of intestinal wound healing [78]. Migration of sube‐
pithelial myofibroblasts can be mediated by a variety of soluble factors such as transforming
growth factor –β (TGFβ), insulin-like growth factor (IGF-1), platelet-derived growth factor-
AB (PDGF-AB), and epidermal growth factor (EGF) [79]. Fibronectin, synthesized by myofi‐
broblasts, is essential and is largely responsible for autocrine induction of intestinal
myfibroblast migration [80].
Wound healing and myofibroblast migration can be affected by chronic inflammation [79].
Subepithelial myofibroblasts isolated from CD patients show a significant reduction in mi‐
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gration response when compared to cells from control patients [81]. Similar reduction in fi‐
broblast migration can be induced by treatment with tumor necrosis factor (TNF) or gamma
interferon (IFN-g) suggesting that an inflammatory environment can induce changes in my‐
ofibroblast function [82]. However, environmental impact on fibroblast migration is com‐
plex. For example, fibroblasts from lung tissue with dense fibrosis show higher PDGF-
driven migratory potential than do fibroblasts from tissues at an early stage of fibrosis [83].
A recent paper compared migratory potential in colonic fibroblasts isolated from CD pa‐
tients with either fistulizing (penetrating) or fibrotic (stricturing) disease [81]. These authors
showed that, while migratory potential is reduced in CD patients with fistulizing disease,
there is in an increase in fibroblast migratory potential in patients with fibrotic disease.
Fibrosis in CD is thought to result from an excessive wound healing response. For reasons
that are not wholly understood, the wound repair process in a subset of CD patients contin‐
ues to progress rather than reaching a termination and allowing for tissue remodeling. Ulti‐
mately, the fibrotic process leads to thickening of the intestinal wall and luminal narrowing
which can result in bowel obstruction. There are three hallmark pathological features which
characterize intestinal stricutres in CD: proliferation of mesenchymal cells including myofi‐
broblasts, smooth muscle cells and fibroblasts; hypertrophy of smooth muscle cells and my‐
ofibroblasts ; and accumulation of excess extracellular matrix proteins [84].
Mesenchymal cells in the intestine can be broadly classed as fibroblasts, smooth muscle cells
or myofibroblasts on the basis of immunostaining properties with antibodies to vimentin (V)
and smooth muscle actin (A) [85, 86]. Fibroblasts are typically V+/A- and are present in the
intestinal submucosal and serosa. Subepithelial myofibroblasts (SEMF) are found adjacent to
intestinal epithelial cells and are V+/A+. Intestinal smooth muscle cells of the muscularis
mucosa and muscularis propria are normally V-/A+. All of these mesenchymal cell types
have been implicated in collagen production in CD patients [69, 87, 88].
Activated fibroblasts or myofibroblasts in tissues undergoing a fibrotic process may be de‐
rived from a variety of sources. There are three general mechanisms which allow for tissue
accumulation of these cells: proliferation of existing tissue fibroblasts, recruitment of fibro‐
blast precursor cells from bone marrow, and transformation either of epithelial cells via epi‐
thelial to mesenchymal transistion (EMT), or of endothelial cells by endothelial to
mesenchymal transition (EndoMT) [89, 90]. Proliferation and activation of tissue fibroblasts
occurs in response to profibrotic signals from infiltrating inflammatory cells or from colonic
epithelial cells exposed to proinflammatory cytokines [91]. Soluble inflammatory mediators
also drive recruitment of fibroblast precursor cells (fibrocytes) from bone marrow. These fi‐
brocytes migrate from the bloodstream into tissues undergoing pathologic fibrosis in re‐
sponse to specific chemokine gradients [89]. EMT and EndoMT are induced by TGFβ [92].
The relative significance of each of mechanisms discussed above to activated fibroblast/
myofibroblast accumulation at the site of injury in CD is not yet fully understood
Smooth muscle hyperplasia surrounded by collagen deposits is the major histologic feature
of fibrostenotic CD. This smooth muscle proliferation expands and disrupts the muscularis
mucosa. Thickening of the muscular layer is associated with an increase in the number of
vimentin-positive cells [93, 94]. In severely affected tissue, even histologically normal mus‐
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cularis mucosa is populated largely by V+/A- and V+/A+ cells rather than the V-/A+ smooth
muscle cells seen in normal muscularis mucosa from non-CD patients. This suggests a tran‐
sition from an enteric smooth muscle cell phenotype toward a fibroblast or myofibroblast
phenotype.
Mesenchymal cells including myofibroblasts as well as smooth muscle cells of the muscula‐
ris mucosa and muscularis propria are the main producers of ECM proteins in the intestine.
These ECM proteins include structural proteins such as collagen, matricellular proteins such
as osteopontin and thrombospondin, and other specialized proteins such as vitronectin and
fibronectin. Collagen is the major ECM component associated with intestinal fibrosis. The
most common collagen subtypes in normal intestine are type I, type III, and type V in order
of abundance. In intestinal fibrosis, there is an increase in total collagen as well as specific
and relative increases in collagen types III and V [95-97].
Fibronectin and vitronectin are ligands for the αVβ3 integrin and, in the presence of fibro‐
nectin, smooth muscle IGF-1-stimulated IGF-1 receptor activation is augmented [98]. This
suggests that increased production of these proteins by smooth muscle cells at sites of intes‐
tinal stricture could activate αVβ3 integrin and further increase secretion of collagen as well
as promote cellular proliferation creating a positive feedback loop which could further sub‐
vert the normal healing process. Fibronectin is also an important mediator in focal adhesion
kinase (FAK) signaling pathways involved in cell migration [99]. Myofibroblasts synthesize
abundant fibronectin which is largely responsible for the autocrine induction of intestinal
myofibroblast migration [100].
The balance between formation and breakdown of ECM proteins determines the net dep‐
osition  in  tissues.  In  intestinal  fibrosis,  mechanisms  to  degrade  ECM  fail  to  keep  pace
with  deposition.  Matrix  metalloproteinases  (MMPs),  a  large  family  of  proteolytic  en‐
zymes,  are  responsible  for  the  breakdown of  ECM components.  The proteolytic  activity
of  MMPs is  controlled by tissue inhibitors  of  metalloproteinases  (TIMPs)  and an imbal‐
ance  between  MMP and  TIMP activity  can  result  in  excessive  deposition  of  ECM pro‐
teins with subsequent fibrosis [101]. Higher levels of constitutive TIMP-1 expression have
been  shown  in  intestinal  myofibroblast  culture  derived  from  fibrotic  CD  patients  than
those from normal individuals [102].
Transforming growth factor –β (TGFβ) is a pleotrophic cytokine and one of the most influ‐
ential factors in fibrotic processes. It is a component of Th17 as well as regulatory T cell type
immune responses as well as a profibrotic mediator. TGFβ exerts profibrotic effects through
its ability to regulate collagen expression and extracellular matrix dynamics. There are three
isoforms of TGFβ: TGFβ1, TGFβ2, and TGFβ3. TGFβ1 activates the canonical Smad signal‐
ing cascade leading to translocation of the Smad receptor complex into the nucleus and reg‐
ulation of gene transcription including ECM genes such as collagen I, collagen III, and
fibronectin [103]. TGFβ also induces EMT in organ-fibrosis inducing diseases [104] and can
to induce EndoMT in vitro via a “noncanonical” signaling pathway [105]. In CD patients,
TGFβ1 and TGFβ3 are increased in in smooth muscle, fibroblasts and myofibroblasts from
the strictured region when compared to normal intestine [102, 106].
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TGFβ family proteins are important in regulating the synthesis and breakdown of ECM pro‐
teins [107]. TGFβ1 downregulates MMP expression and enhances the expression of TIMP-1
[101]. Characterization of the role of TGFβ expression in disease has been done using myofi‐
broblast cultures. Myofibroblasts from normal intestine predominantly express TGFβ3 while
those patients with fibrotic CD had significantly lower expression of TGFβ3 and higher lev‐
els of TGFβ1 and TGFβ2 [102, 108].
Insulin-like growth factor has also been implicated in the pathogenesis of stricture forma‐
tion [109].  Intestinal smooth muscle cells  express IGF-1 which activates the IGF-1 recep‐
tor  thereby  regulating  smooth  muscle  cell  hyperplasia  by  simultaneously  stimulating
proliferation  and  inhibiting  apoptosis  [110,  111].  Studies  using  CD tissue  from patients
undergoing intestinal resection show increased expression of both IGF-1 as well as syner‐
gistic IGF binding protein 5 (IGFBP-5) in lesional tissue [112].  Localization studies show
IGF-1 is upregulated in smooth muscle cells in regions of stricture when compared to tis‐
sue from surgical margins.
7. Preclinical models
A major challenge facing scientists interested in developing treatments for CD-associated fi‐
brotic disease is the need for a robust animal model which develops morphologic features
and utilizes pathogenic processes similar to those characterized for the human disease. Pre‐
clinical models should provide a consistent environment for testing intervention strategies
and quantifying outcomes. At present, no animal model exists which reproduces the unique
histologic features associated with CD intestinal strictures. There are several models which
address some aspects of CD stricture pathogenesis and those are reviewed below.
Intestinal inflammation and fibrosis can be induced in rats by injection of peptidoglycan-
polysaccharide (PG-PS) into the intestinal wall or by repeated rounds of trinitrobenzene sul‐
fonic acid (TNBS) treatment [113, 114]. PG-PS injection causes acute inflammation which
peaks by 2 days followed by remission. Spontaneous reactivation of inflammation occurs in
genetically susceptible rat strains by 12-17 days and is characterized by progressive trans‐
mural granulomatous enterocolitis [115]. Multiple cycles of intrarectal injection of TNBS in
ethanol also induces a granulomatous transmural inflammatory response which becomes
dominated by chronic inflammation and fibrosis after cycle 4[113, 116]. This model features
transmural collagen deposition which is most prominent in the submucosa. Smooth muscle
proliferation and expansion into the submucosal space is not a feature of these models.
Given that no existing preclinical model completely mimics changes found in human CD fi‐
brostenosis, assessment of the value of models should be based on the presence of pathways
of interest as well as tractability in testing potential therapeutic entities. These rat models
show transmural inflammation associated with transmural fibrosis as well as overexpres‐
sion of TGFβ and/or IGF-1 in a manner consistent with human disease [116-119]. However,
given the availability of reagents and other research tools, mouse models of intestinal fibro‐
sis are more desirable to the research community.
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While many murine models of inflammatory colitis or enteritis exist, these models are gen‐
erally not suitable for study the pathogenesis of stricture formation or for testing interven‐
tion strategies because they generate very little intestinal fibrosis. Fibrotic models have been
challenging to develop given the inherent resistance of mice when compared to other spe‐
cies in development of fibrotic disease [94]. However, progress is being made in this area.
Ileocecal resection is a common surgical intervention in CD and is associated with high rates
of disease recurrence[120]. After surgery, recurrence of inflammation and/or fibrosis typical‐
ly occurs at the anastomosis and in the small intestine immediately upstream of the anasto‐
mosis. A model of ileocecal resection in IL-10 gene knockout mice has been described which
develops inflammation and fibrosis both at the anastomosis site and in other regions of the
small intestine [121]. This approach is attractive because it models a major clinical feature of
CD fibrostenotic disease and is highly relevant to future clinical trials where therapeutics
targeting CD fibrosis will likely be evaluated for prevention of postsurgical recurrence.
However, IL-10 null mice do not spontaneously develop small intestinal inflammation and
this surgical approach may need to be combined with one of the existing murine ileitis mod‐
els to achieve the most relevant preclinical model.
Chronic  TNBS treatment  has  been used to  induce colitis  in  mice as  well  as  rats.  In  the
mouse, TNBS with concomitant administration of ethanol as an epithelial barrier disrupt‐
er induces intestinal  ulceration and inflammation.  This model is  widely used to investi‐
gate acute inflammation in the gut. Chronic TNBS treatment has been tested in an effort
to develop a more robust intestinal fibrosis model in mouse [122].  This model has been
reported  to  have  some  common  features  with  CD  including  transmural  inflammation
and stricturing with proximal  dilation and fibrosis.  Affected animals  have increased ex‐
pression of MMP-1 and collagen type 1. Fibrosis in this model can be enhanced by treat‐
ment  with  indomethacin,  a  cyclooxygenase  (COX)  inhibitor  which  can  block  the  anti-
fibrotic effects of COX-2 [123].
Dextran sulfate sodium added to drinking water is frequently used to induce epithelial in‐
jury and acute colitis in mice. Fibrosis with associated increase in collagen, TGFβ, and ma‐
trix metalloproteinase expression has been described in C57BL6 mice following a single 5
day cycle of DSS exposure [124]. The authors were also able to show an increase in fibro‐
blasts (V+/A-) and myofibroblasts (V+/A+ ) cells in the mucosa and submucosa. While this
likely reflects a primary intestinal wound healing response rather than the chronic fibrotic
process suggested by the authors, it is worth considering if this could be a useful pathway
model which might allow rapid testing the effect of therapeutic candidates on specific ele‐
ments of the wound healing/fibrotic response. Other groups have investigated the effect of
multiple cycles of DSS exposure on fibrotic response in FVB-N and C57BL6 mice [125]. A
single cycle of DSS exposure in C57BL6 mice does result in ECM deposition followed by
mucosal repair and normalized mucosal architecture. Multiple cycles of DSS exposure did
not result in enhanced fibrosis in FVB-N mice, however, it did result in prolongation of a
fibrotic response in C57BL6 mice as measured by procollagen α1(I) promoter-GFP reporter
transgene reporter activity. Further characterization will be needed to determine the utility
of this model.
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Salmonella species are facultative intracellular gram negative bacteria which cause a range of
illnesses including, but not limited to, enterocolitis [126]. Salmonella enterica serovar Typhi‐
murium is an enteric bacterial pathogen which normally causes little intestinal pathology in
mice but instead mimics human typhoid. However, a model which utilizes oral streptomy‐
cin pretreatment has been developed which allows study of S. Typhimurium-induced cecal
inflammation [127]. This work has been extended by utilizing attenuated S. Typhimurium
strains or by infecting resistant mouse strains which carry a functional nramp1 gene to in‐
duce chronic infection which results in intestinal fibrosis characterized by transmural colla‐
gen deposition and accumulation of fibroblasts in the intestinal submucosa [128]. While
increase in collagen deposition is observed throughout the colon, the most intense lesions
are present in the cecum. The Salmonella model of intestinal fibrosis is unique in that it is
induced by bacterial colitis. It results in a relatively long term fibrotic process where fibrosis
can be observed in the cecal submucosa at least to day 40 post infection. Similar to human
CD, increased TGFβ and IGF-1 are associated with fibrosis in this model.
8. Prevention or treatment of CD fibrosis
While considerable progress has been made, the pathophysiology of fibrostenotic disease in
CD patients is incompletely understood. The drug development challenges this creates are
greatly compounded by the absence of a well defined and widely accepted preclinical ani‐
mal model of intestinal fibrosis. Recognition of the unmet need for medical interventions
which can effectively prevent or treat CD fibrostenotic disease drives ongoing research in
both areas. Despite the challenges, a number of potential therapeutic agents or pathways
have undergone preliminary testing. A few of these results are summarized below. The data
available for all of these agents is quite limited.
Prostaglandins (PGE1 and 2) are known to inhibit smooth muscle proliferation as well as fi‐
broblast proliferation induced by proinflammatory cytokines [129, 130]. Reduced PGE2 lev‐
els are associated with development of fibrosis in idiopathic pulmonary fibrosis (IPF) [131]
and indomethacin treatment, which inhibits PGE2, increases fibrosis in the chronic murine
TNBS model of colon fibrosis. However, mice deficient in prostaglandin endoperoxide syn‐
thase (Ptgs) 2, an enzyme involved in prostaglandin production, showed deficient wound
healing following full-thickness colonic biopsy so the effects of prostaglandins may be com‐
plex and, perhaps, dependent on the stage of wound healing [132]. Phosphatidyl choline, a
polyunsaturated fatty acid which is a precursor to PGE2, has been shown to decrease stric‐
ture formation in the rat TNBS intestinal fibrosis model [133]. These data suggest a role for
PGE2 in intestinal wound healing and fibrosis but the potential for a therapeutic role re‐
quires further investigation.
The steroid hormone retinoic acid (RA) is another potential agent for modification of fibrosis
in CD. RA has been shown to have effects on human fibroblast proliferation in cells isolated
from IPF lungs [134] and to protect against bleomycin-induced pulmonary fibrosis in mice
[135]. More recently, RA has been shown to reduce intestinal fibrosis in the chronic TNBS
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mouse model of intestinal fibrosis [123]. Much more research will be needed to determine if
RA has promise as a fibrosis modifying agent in CD.
Resveratrol (trans-3,5,4’-trihydroxystilbene) is a phytoalexin found in a variety of plant
products including berries, peanuts, grapes and red wine. It has been shown to reduce in‐
flammation in rat colitis [136]. Resveratrol has also been shown to reduce activation of NF-
kB in TNBS colitis [137]. A recent paper reports that resveratrol exposure results in
decreased collagen synthesis as well as apoptosis in rat intestinal smooth muscle cells [138].
While the data on resveratrol is quite preliminary, the data is of interest because it targets
smooth muscle rather than the fibroblasts or myofibroblasts.
Anti-inflammatory and anti-fibrotic effects of the cholesterol lowering 3-hydroxy-3-methyl‐
glutaryl-CoA reductase inhibitors (statins) have been reported. Statins may play an anti-fi‐
brotic role through inhibition of the activation and proliferation of fibroblasts and by
inducing apoptosis of activated fibroblasts [139]. Angiotensin type 1 receptor blockers [140]
and the angiotensin-converting enzyme inhibitor captopril [141] have also been proposed as
fibrosis inhibitors.
Fibrosis has traditionally been considered an irreversible process. Further testing of these
and other agents which have potential to block initiation or inhibit progression of fibrosis
may also reveal if medical treatment has the potential to reverse existing fibrotic lesions. Re‐
search to further characterize the underlying pathophysiologic processes involved in fibros‐
tenotic disease and to test potential therapeutic approaches remains important to the goal of
fully meeting CD therapeutic needs.
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